This test provides reanalysis and interpretation of sequencing data from a previous whole exome quad test sequenced at Revvity Omics.
Test Code | D0514 |
---|---|
Test Summary |
This test provides reanalysis and interpretation of sequencing data from a previous whole exome quad test sequenced at Revvity Omics. |
Turn Around Time | 2 - 4 weeks |
Acceptable Sample Types | Reanalysis Only |
Acceptable Billing Types | Institutional Billing , Self (patient) Payment |
NY Approved | Yes |
CPT Codes** | 81479(x2), 81417(x4), 81460(x1) |
This test involves reanalysis and interpretation of previously generated data from a Revvity Omics whole exome sequencing test. All variants identified will be analyzed according to American College of Medical Genetics and Genomics (ACMG) guidelines. Our WES test will reliably detect the majority of copy number variations (CNVs) of 3 exons or greater as well as additional common deletion events. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. The WES assay will also detect microdeletion/duplication events greater than 500kb in clinically relevant regions, although follow-up testing may be warranted to better delineate the exact size of the event and confirm breakpoints. It is recommended that updated clinical notes and phenotypes are provided to aid in the reanalysis.
FASTQ files from a whole exome sequencing test previously completed at Revvity Omics are utilized for reanalysis. A base is considered to have sufficient coverage at 20X and an exon is considered fully covered if all coding bases plus three nucleotides of flanking sequence on either side are covered at 20X or more. A list of these regions, if any, is available upon request. Alignment to the human reference genome (GRCh37) is performed and annotated variants are identified in the targeted region. Variants reviewed have a minimum coverage of 8X and an alternate allele frequency of 20% or higher. Indel and single nucleotide variants (SNVs) may be confirmed by Sanger sequence analysis before reporting at director discretion. This assay cannot detect variants in regions of the exome that are not covered, such as deep intronic, promoter and enhancer regions, areas containing large numbers of tandem repeats, and variants in mitochondrial DNA. Copy number variation (CNV) analysis detects deletions and duplications; in some instances, due to the size of the exons, sequence complexity, or other factors, not all CNVs may be analyzed or may be difficult to detect. When reported, copy number variant size is approximate. Actual breakpoint locations may lie outside of the targeted regions. CNV analysis will not detect tandem repeats, balanced alterations (reciprocal translocations, Robertsonian translocations, inversions, and balanced insertions), methylation abnormalities, triploidy, and genomic imbalances in segmentally duplicated regions. This assay is not designed to detect mosaicism; possible cases of mosaicism may be investigated at the discretion of the laboratory director. The external FASTQ data is analyzed using Illumina DRAGEN Bio-IT Platform v.3.10.8. Tertiary data analysis is performed using SnpEff v5.0 and Revvity Omics’ internal ODIN v.1.01 software. CNV and absence of heterozygosity are assessed using BioDiscovery’s NxClinical v6.1 software.
Collection |
This test is performed on data that has already been generated by Revvity Omics. |
---|---|
Sample Condition |
N/A |
Shipping |
N/A |
Select the correct test for your patient, and download and fill out the Clinical Genomics test requisition form.
Obtain a sample for testing from the patient using one of the provided Revvity Omics test packs.
Send samples and all required forms back to Revvity for processing using pre-paid shipping label.
We are here to answer your questions.